PINCH-2 expression in cancers involving serosal effusions using quantitative PCR

Cytopathology

Volumn 22, Issue 1, 2011, Pages 22-29

  Yuan, Y ^a   Dong, H P ^a   Nymoen, D A ^a   Nesland, J M ^a,b   Wu, C ^c   Davidson, B ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Cytology; Flow cytometry; Malignant mesothelioma; PINCH 2; Quantitative PCR; Serous effusions

Indexed keywords

MESSENGER RNA; PROTEIN; PROTEIN PINCH 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CELL ADHESION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; METASTASIS; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SEROSA;

ADENOCARCINOMA; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DNA PRIMERS; DNA-BINDING PROTEINS; EXUDATES AND TRANSUDATES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MESOTHELIOMA; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 78651262554     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2010.00757.x     Document Type: Article

References (37)

1. Bedrossian CWM, ed. Malignant effusions: A Multimodal Approach to Cytologic Diagnosis. New-York: Igaku-Shoin; 1994.
2. Davidson B. The biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog 2007;13:189-227.
3. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary view. Cancer 2001;93:293-308.
4. Ordóñez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol 2006;13:16-25.
5. Suster S, Moran CA. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol 2006;13:316-29.
6. Ordóñez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update Hum Pathol 2007;38:1-16.
7. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 2008;132:397-401.
8. Davidson B, Zhang Z, Kleinberg L et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2006;12:5944-50.
9. Wu C. PINCH, N(i)ck and the ILK: Network wiring at cell-matrix adhesions. Trends Cell Biol 2005;15:460-6.
10. Zhang Y, Chen K, Guo L, Wu C. Characterization of PINCH-2, a new focal adhesion protein that regulates the PINCH-1-ILK interaction, cell spreading, and migration. J Biol Chem 2002;277:38328-38.
11. Braun A, Bordoy R, Stanchi F et al. PINCH2 is a new five LIM domain protein, homologous to PINCH and localized to focal adhesions. Exp Cell Res 2003;284:239-50.
12. Kim SK, Jang HR, Kim JH et al. The epigenetic silencing of LIMS2 in gastric cancer and its inhibitory effect on cell migration. Biochem Biophys Res Commun 2006;349:1032-40.
13. Davidson B, Risberg B, Kristensen G et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virchows Arch 1999;435:43-9.
14. Davidson B, Nielsen S, Christensen J et al. The role of Desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-12.
15. Beillard E, Pallisgaard N, van der Velden VH et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003;17:2474-86.
16. Dong HP, Holth A, Berner A, Davidson B, Risberg B. Flow cytometric immunphenotyping of epithelial cancer cells in effusions- Technical considerations and pitfalls. Cytometry B Clin Cytom 2007;72B:332-43.
17. Yuan Y, Nymoen DA, Dong HP et al. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol 2009;40:1453-60.
18. Fukuda T, Chen K, Shi X, Wu C. PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. J Biol Chem 2003;278:51324-33.
19. Zhang Y, Chen K, Tu Y, Wu C. Distinct roles of two structurally closely related focal adhesion proteins, alpha-parvins and beta-parvins, in regulation of cell morphology and survival. J Biol Chem 2004;279:41695-705.
20. Yang Y, Guo L, Blattner SM et al. Formation and phosphorylation of the PINCH-1-integrin linked kinase-alpha-parvin complex are important for regulation of renal glomerular podocyte adhesion, architecture, and survival. J Am Soc Nephrol 2005;16:1966-76.
21. Dougherty GW, Chopp T, Qi SM, Cutler ML. The Ras suppressor Rsu-1 binds to the LIM 5 domain of the adaptor protein PINCH1 and participates in adhesion-related functions. Exp Cell Res 2005;306:168-79.
22. Cheng J, Zhang J, Merched A et al. Mechanical stretch inhibits oxidized low density lipoprotein-induced apoptosis in vascular smooth muscle cells by up-regulating integrin alphavbeta3 and stablization of PINCH-1. J Biol Chem 2007;282:34268-75.
23. Li Y, Dai C, Wu C, Liu Y. PINCH-1 promotes tubular epithelial-to-mesenchymal transition by interacting with integrin-linked kinase. J Am Soc Nephrol 2007;18:2534-43.
24. Dougherty GW, Jose C, Gimona M, Cutler ML. The Rsu-1-PINCH1-ILK complex is regulated by Ras activation in tumor cells. Eur J Cell Biol 2008;87:721-34.
25. Chen K, Tu Y, Zhang Y et al. PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells. J Biol Chem 2008;283:2508-17.
26. Givant-Horwitz V, Davidson B, van de Putte G et al. Expression of the 67kDa laminin receptor and the α6 integrin subunit in serous ovarian carcinoma. Clin Exp Metastasis 2003;20:599-609.
27. Davidson B, Goldberg I, Reich R et al. The αv and β1 integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 2003;90:248-57.
28. Elloul S, Bukholt Elstrand M, Nesland JM et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005;103:1631-43.
29. Elloul S, Silins I, Trope' CG et al. Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch 2006;449:520-8.
30. Kleinberg L, Holth A, Trope' CG, Reich R, Davidson B. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol 2008;39:747-57.
31. Kleinberg L, Flørenes VA, Silins I et al. Nuclear expression of Survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 2007;109:228-38.
32. Kleinberg L, Dong HP, Holth A et al. Cleaved caspases and NF-κB p65 are prognostic factors in metastatic ovarian carcinoma. Hum Pathol 2009;40:795-806.
33. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol 2006;30:878-82.
34. Kleinberg L, Holth A, Fridman E et al. The diagnostic role of claudins in serous effusions. Am J Clin Pathol 2007;127:928-37.
35. Davidson B, Baekelandt M, Shih IeM. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol 2007;35:756-60.
36. Davidson B, Skrede M, Silins I et al. Low molecular weight cyclin E forms differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 2007;110:1264-71.
37. Yuan Y, Nymoen DA, Dong HP et al. Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol 2009;33:1673-82.